ALICE SCHROEDER,1 UTA ECKHARDT,1 BRUNO STIEGER,1 RONALD TYNES,2 CLAUDIO D. SCHTEINGART,3,4 ALAN F. HOFMANN,3 PETER J. MEIER,1 AND BRUNO HAGENBUCH1 1Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, CH-8091 Zurich; 2Drug Metabolism and Pharmakokinetics, Novartis Pharma, CH-4002 Basel, Switzerland; 3Division of Gastroenterology, Department of Medicine,...

“This study illustrates that we have the potential to prevent muscle wasting and promote muscle growth in cell and animal models,” says corresponding author Dr. David Glass, Executive Director in Musculoskeletal Disease at the Novartis Institutes for BioMedical Research. “We’re now testing BYM338 in the clinic.” This is an Investigational drug that is being tested in the clinic. Therefore safet...

Experimental preventive therapies are now entering clinical trials, ushering in a new era of research. For instance, a new Alzheimer’s disease prevention trial [3]—which is slated to begin in late 2015 and jointly run by teams from Novartis and the Banner Alzheimer’s Institute in Phoenix, Arizona—is giving people a reason to consider genetic testing. It has also prompted researchers to think de...

Novartis Foundation sponsored a Symposium which brought together a group of experimental immunologists, theoretical immunologists, and bioinformaticians to discuss the new field of immunoinformatics. The discussion focused on immunological databases, antigen processing and presentation, immunogenomics, host-pathogen interactions, and mathematical modelling of the immune system. A main conclusio...

Potential Conflicts of Interest: Antonio G. Renta, MD, is a clinical cardiologist in private practice in Hato Rey, Puerto Rico, and has disclosed the following relevant financial relationships: Dr. Renta served as a speaker in a number of promotional scientific activities for the Merck, Forest, Boehringer, and Novartis pharmaceutical companies. He received payment for his participation in a cli...

Division of Pharmacology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa (P.S.F., B.R.) Division of Drug Metabolism and Pharmacokinetics, Novartis Institute of Biomedical Research, Basel, Switzerland (H.G., H.S., A.J.) Synexa Life Sciences, Montague Gardens, Cape Town, South Africa (P.J.D.) Division of Medical Microbiology, Faculty of Medicine and H...

Regulation in Metabolism Group/Membrane Group Colloquium Organized by S. Cockcroft (Department of Physiology, University College London) and P. Hawkins (Department of Signalling, The Babraham Institute), Edited by S. Cockcroft and Sponsored by Eschelon Research Laboratory, Eli Lilly and Co., The Gatsby Charitable Foundation, Merck Sharpe and Dohme, Novartis, Smithkline Beecham, Unilever, Yamano...

The power of patient-centric events stems from the dialogue that takes place – dialogue with the power to effect positive change. This was particularly true of the second Chronic Obstructive Pulmonary Disease (COPD) Global Patient Leadership Summit [3] in Paris, as patients from around the world gathered to discuss the issues closest to the heart of the COPD community. For more information on C...

The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Novartis Ireland Ltd) economic dossier on the cost effectiveness of secukinumab (Cosentyx®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the ne...

On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib mesylate (Gleevec). The patent application failed to meet the requirements for patentability under Indian law. The global public health community followed the case closely. Its outcome could affect the Indian generics industry - an important supplier...